26. Pettus J., Santos Cavaiola T., Tamborlane W.V., Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016; 32 (6): 478–96.
27. Ametov A.S., Valitov B.I., Chernikova N.A. Therapeutic training: past, present and future. akharniy diabet [Diabetes Mellitus]. 2012; 15 (1): 71–7. (in Russian)
28. Salikhova A.F., Farkhutdinova L.M., Allaberdina D.U. Obesity: an epidemic of the 21st century. Previous studies and modern view on the problem. Vestnik akademii nauk respubliki Bashkortostan [Bulletin of the Academy of Sciences of the Republic of Bashkortostan]. 2012; 17 (1): 32–8. (in Russian)
29. Akimova V.E. Akimov V.Yu. Overweight in middle-aged men: population monitoring. Vrach [Physician]. 2021; 32 (2): 59–63. (in Russian)
30. Oganov R.G., Simanenkov V.I., Bakulin I.G., Bakulina N.V., Barbarash O.L., Boytsov S.A., et al. Comorbid pathology in clinical practice. Diagnostic and treatment algorithms. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2019; 18 (1): 5–66. (in Russian)
31. Krasnoperova O.I., Smirnova E.I., Merzlova N.B. Factors leading to the development of obesity in children and contributing to its transformation into metabolic syndrome. Fundamental’nye issledovaniya [Fundamental Researches]. 2012; 4-2: 306–10. (in Russian)
32. Hammarstedt A., Gogg S., Hedjazifar S., Nerstedt A., Smith U. Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity. Physiol Rev. 2018; 98 (4): 1911–41.
33. Verbovoy A.F., Sharonova L.A., Lomonova T.V. Adipokines and echocardiographic parameters in men with diabetes mellitus type 2 and hypothyroidism. Kardiologiya: novosti, mneniya, obucheniye. [Cardiology: News, Opinions, Training]. 2019; 7 [1 (20)]: 8–14. (in Russian)
34. Akhmerova R.I. The relationship of hormonal-metabolic parameters and the functional state of the myocardium in women with type 2 diabetes mellitus and bronchial asthma. Vrach-aspirant [Postgraduate Doctor]. 2014; 67 (6.2): 208–17. (in Russian)
35. Lebedev P.A., Verbovoy A.F., Mateesku K.A, Aleksandrov M.Yu., Paranina E.V. The paradox of obesity and postinfarction remodeling in patients with the Q-wave myocardial infarction. Kardiologiya: novosti, mneniya, obucheniye. [Cardiology: News, Opinions, Training]. 2018; 3 (18): 74–82. (in Russian)
36. Khripun I.A., Khripun A.V. Endothelial dysfunction diagnostic «Platform» in patients with diabetes mellitus. Meditsinskiy vestnik Yuga Rossii [Medical Bulletin of the South of Russia]. 2022; 13 (1): 109–16. (in Russian)
37. Banks W.A., Niehoff M.L., Martin D., Farrell C.L. Leptin transport across the blood-brain barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res. 2002; 950 (1–2): 130–6.
38. Seoane-Collazo P., Martínez-Sánchez N., Milbank E., Contreras C. Incendiary leptin. Nutrients. 2020; 12 (2): E472.
39. Friedman J.M. The function of leptin in nutrition, weight, and physiology. Nutr Rev. 2002; 60 (10 pt 2): S1–14.
40. Farooqi I.S., O’Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol. 2014; 223 (1): T63–70.
41. Dolgikh Yu.A. Verbovoy A.F., Mitroshina E.V. Assessment of hormonal and metabolic parameters and the state of the cardiovascular system in obesity, manifested in adolescence in young men. Spravochnik vracha obshchey praktiki [General Practitioner’s Handbook]. 2013; (1): 41–9. (in Russian)
42. Martins M. do C., Lima Faleiro L., Fonseca A. Relação entre a leptina, a massa corporal e a síndrome metabólica numa amostra da população adulta [Relationship between leptin and body mass and metabolic syndrome in an adult population]. Rev Port Cardiol. 2012; 31 (11): 711–9.
43. Liu W., Zhou X., Li Y., Zhang S., Cai X., Zhang R., et al. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: a population-based study. Medicine (Baltimore). 2020; 99 (6): e19052.
44. Farooqi I.S., Matarese G., Lord G.M., et al. Beneficial effects of leptin on obesity, T cell hyporespon-siveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002; 110: 1093–103.
45. Flier J.S. Hormone resistance in diabetes and obesity: insulin, leptin, and FGF21. Yale J Biol Med. 2012; 85 (3): 405–14.
46. Oral E.A., Simha V., Ruiz E. et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002; 346: 570–8.
47. Hukshorn C.J., Westerterp-Plantenga M.S., Saris W.H. Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. Am J Clin Nutr. 2003; 77 (4): 771–6.
48. Roth J., Weyer C., Anderson C., et al. Leptin re-sponsivity restored in leptin-resistantdiet-induced obese (DIO) rats: synergistic actions of amylin and leptin for reduction in body weight (BW) and fat. In: American Diabetes Association 66th Scientific Sessions. 2006. Abstr. 52-LB.
49. Lam N.T., Covey S.D., Lewis J.T., et al. Leptin resistance following over-expression of protein tyrosine phosphatase 1B in liver. J Mol Endocrinol. 2006; 36: 163–74.
50. Chen K., Li F., Li J., et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006; 12: 425–32.
51. Wang M.Y., Orci L., Ravazzola M., Unger R.H. Fat storage in adipocytes requires inactivation of leptin’s paracrine activity: implications for treatment of human obesity. Proc Natl Acad Sci USA. 2005; 102: 18 011–6.
52. Liu J., Lee J., Salazar Hernandez M.A., Mazitschek R., Ozcan U. Treatment of obesity with celastrol. Cell. 2015; 161 (5): 999–1011.
53. Ghadge A.A., Khaire A.A. Leptin as a predictive marker for metabolic syndrome. Cytokine. 2019; 121: 154735.
54. Wu P., Wen W., Li J., Xu J., Zhao M., Chen H., et al. Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 Inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. Horm Metab Res. 2019; 51 (8): 487–94.
55. Okada-Iwabu M., Iwabu M., Yamauchi T., Kadowaki T. Structure and function analysis of adiponectin receptors toward development of novel antidiabetic agents promoting healthy longevity. Endocr J. 2018; 65 (10): 971–7.
56. Turer A.T., Scherer P.E. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012; 55 (9): 2319–26.
57. Fisman E.Z., Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014; 13: 103.
58. Verbovoy A.F., Tsanava I.A., Verbovaya N.I. Adipokines and metabolic parameters in patients with type 2 diabetes mellitus in combination with gout. Ozhirenie i metabolizm [Obesity and Metabolism]. 2016; 3 (1): 20–4. (in Russian)
59. Mitroshina E.V. Relationship between adiponectin levels and lipid and carbohydrate metabolism in boys and men with obesity manifested in puberty. Izvestiya vysshikh uchebnykh zavedeniy. Povolzhskiy region. Meditsinskie nauki [Proceedings of Higher Educational Institutions. Volga Region. Medical Sciences]. 2011; 18 (2): 11–8. (in Russian)
60. Banerjee A., Khemka V.K., Roy D., Poddar J., Roy T.K.S., Karnam S.A. Role of serum adiponectin and vitamin D in prediabetes and diabetes mellitus. Can J Diabetes. 2017; 41 (3): 259–65.
61. Abdella N.A., Mojiminiyi O.A. Clinical applications of adiponectin measurements in type 2 diabetes mellitus: screening, diagnosis, and marker of diabetes control. Dis Markers. 2018; 5: 5187940.
62. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006; 46: 101–22.
63. Okada-Iwabu M., Yamauchi T., Iwabu M., Honma T., Hamagami K., Matsuda K., et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013; 503 (7477): 493–9.
64. Holland W.L., Scherer P.E. Cell Biology. Ronning after the adiponectin receptors // Science. 2013; 342 (6165): 1460–1.
65. Bhat I.A., Kabeer S.W., Reza M.I., Mir R.H., Dar M.O. AdipoRon: a novel insulin sensitizer in various complications and the underlying mechanisms: a review. Curr Mol Pharmacol. 2020; 13 (2): 94–107.
66. Nigro E., Daniele A., Salzillo A., Ragone A., Naviglio S., Sapio L. AdipoRon and other adiponectin receptor agonists as potential candidates in cancer treatments. Int J Mol Sci. 2021; 22 (11): 5569.
67. Takenaga K., Akimoto M., Koshikawa N., Nagase H. Obesity reduces the anticancer effect of AdipoRon against orthotopic pancreatic cancer in diet-induced obese mice. Sci Rep. 2021; 11 (1): 2923.
68. Gu D., Shi Y., Gong Z., Xia T., Ren H., He D., et al. AdipoRon, an adiponectin receptor agonist, protects contrast-induced nephropathy by suppressing oxidative stress and inflammation via activation of the AMPK pathway. Clin Exp Nephrol. 2020; 24 (11): 989–98.
69. Kim Y., Lim J.H., Kim M.Y., Kim E.N., Yoon H.E., Shin S.J., et al. The adiponectin receptor agonist AdipoRon ameliorates diabetic nephropathy in a model of type 2 diabetes. J Am Soc Nephrol. 2018; 29 (4): 1108–27.
70. Gusenbekova D.G., Ametov A.S., Butaeva S.G. Dipeptidyl peptidase-4 inhibitors: new opportunities for effective glycemic control by correcting lipid metabolism disorders in patients with type 2 diabetes mellitus. Farmateka [Pharmateca]. 2015; (10): 49–54. (in Russian)
71. Litvinenko V.M., Ametov A.S. Adipokine status of patients with newly diagnosed type 2 diabetes mellitus and visceral obesity during dapagliflozin therapy. In: Sakharniy diabet – pandemiya XXI v. Sbornik tezisov VIII (XXV) Vserossiyskogo diabetologicheskogo kongressa s mezhdunarodnym uchastiyem [Diabetes Mellitus is a Pandemic of the 21st Century. Collection of abstracts of the VIII (XXV) All-Russian Diabetology Congress with international participation]. Moscow, 2018: 289–90. (in Russian)
72. Ionescu D.D.; PREFER Investigators. Anti-hypertensive efficacy of perindopril 5–10 mg/day in primary health care: an open-label, prospective, observational study. Clin Drug Investig. 2009; 29 (12): 767–76.
73. Koz C., Baysan O., Yokusoglu M., et al. The effects of perindopril on aortic elasticity and inflammatory markers in hypertensive patients. Med Sci Monit. 2009; 15 (7): PI41–5.
74. Nedogoda S., Ledyaeva A.A., Chumachok E.V., et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013; 33: 553–61.